Skip to Content
Merck

In vivo sustained release of siRNA from solid lipid nanoparticles.

ACS nano (2011-11-15)
Tatsiana Lobovkina, Gunilla B Jacobson, Emilio Gonzalez-Gonzalez, Robyn P Hickerson, Devin Leake, Roger L Kaspar, Christopher H Contag, Richard N Zare
ABSTRACT

Small interfering RNA (siRNA) is a highly potent drug in gene-based therapy with a challenge of being delivered in a sustained manner. Nanoparticle drug delivery systems allow for incorporating and controlled release of therapeutic payloads. We demonstrate that solid lipid nanoparticles can incorporate and provide sustained release of siRNA. Tristearin solid lipid nanoparticles, made by nanoprecipitation, were loaded with siRNA (4.4-5.5 wt % loading ratio) using a hydrophobic ion pairing approach that employs the cationic lipid DOTAP. Intradermal injection of these nanocarriers in mouse footpads resulted in prolonged siRNA release over a period of 10-13 days. In vitro cell studies showed that the released siRNA retained its activity. Nanoparticles developed in this study offer an alternative approach to polymeric nanoparticles for encapsulation and sustained delivery of siRNA with the advantage of being prepared from physiologically well-tolerated materials.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glyceryl tristearate, ≥99%
Sigma-Aldrich
Glyceryl tristearate, technical